38. A method of using the host cell of claim 36 or 37 to produce an antibody, comprising culturing the host cell of claim 36 or 37 under suitable conditions and recovering said antibody.

39. An antibody produced by the method of claim 38.

40. A sterile pharmaceutical composition comprising the antibody of any one of claims 1-33 and 39 and a pharmaceutically acceptable carrier.

41. Use of an antibody of any one of claims 1 to 33 or a pharmaceutical composition of claim 40 for the manufacture of a medicament for ~~A method for~~ treating a disease, condition or disorder associated with TGFβ expression in a subject in need thereof ~~comprising the step of administering to a subject in need thereof a therapeutically effective amount of an antibody of any one of claims 1 to 33 or a pharmaceutical composition of claim 40~~.

42. The ~~method~~ use of claim 41, wherein the disease, condition or disorder is selected from the group consisting of cancer, eye diseases, conditions or disorders, ophthalmic fibroses or fibrosis of the eye, pulmonary fibrosis, idiopathic pulmonary fibrosis, peribronchiolar fibrosis, interstitial lung disease, chronic obstructive pulmonary disease (COPD), small airway disease (e.g., obstructive bronchiolitis), emphysema, adult or acute respiratory distress syndrome (ARDS), acute lung injury (ALI); pulmonary fibrosis due to infectious or toxic agents; kidney fibrosis, glomerulonephritis (GN) of all etiologies, mesangial proliferative GN, immune GN, and crescentic GN, glomerulosclerosis, tubulointerstitial injury, renal interstitial fibrosis, renal fibrosis and all causes of renal interstitial fibrosis, renal fibrosis resulting from complications of drug exposure, cyclosporin treatment of transplant recipients, HIV-associated nephropathy, transplant necropathy, diabetic kidney disease (diabetic nephropathy), nephrogenic systemic fibrosis, diabetes, idiopathic retroperitoneal fibrosis, scleroderma, liver fibrosis, hepatic diseases associated with excessive scarring and progressive sclerosis, liver cirrhosis, disorders of the biliary tree, hepatic dysfunction attributable to infections, fibrocystic diseases, cardiovascular diseases, congestive heart failure, dilated cardiomyopathy; myocarditis; vascular stenosis cardiac fibrosis (post-infarction cardiac fibrosis), post myocardial infarction, left ventricular hypertrophy, veno-occlusive disease, restenosis, post-angioplasty restenosis, arteriovenous graft failure, atherosclerosis, hypertension, hypertensive heart disease, cardiac hypertrophy, hypertrophic cardiomyopathy, heart failure, disease of the aorta, progressive systemic sclerosis, polymyositis, systemic lupus erythematosus, dermatomyositis, fascists, Raynaud's

syndrome, rheumatoid arthritis, , Peyronie's disease, systemic sclerosis, post-spinal cord injury, osteoporosis, Camurati-Engelmann disease, Crohn's disease, scarring, Marfan syndrome, premature ovarian failure, Alzheimer's Disease and Parkinson's Disease, fibrosis due to surgical incisions or mechanical trauma, fibrosis associated with ocular surgery; and excessive or hypertrophic scar or keloid formation in the dermis occurring during wound healing resulting from trauma or surgical wounds.

43. The ~~method~~ use of claim 42, wherein the disease, condition or disorder is an eye disease, condition or disorder selected from the group consisting of fibroproliferative disorders, fibrosis of the eye, ophthalmic fibroses, retinal dysfunction, fibrosis associated with retinal dysfunction, wet or dry macular degeneration, proliferative vitreoretinopathy, vitreoretinopathy of any etiology, fibrosis associated with ocular surgery such as treatment of glaucoma, retinal reattachment, cataract extraction, or drainage procedures of any kind, scarring in the cornea and conjunctiva, fibrosis in the corneal endothelium, alkali burn (e.g., alkali burn to the cornea), post-cataract surgery fibrosis of the lens capsule, excess scarring in the tissue around the extraocular muscles in the strabismus surgery, anterior subcapsular cataract and posterior capsule opacification, anterior segment fibrotic diseases of the eye, fibrosis of the corneal stroma (e.g., associated with corneal opacification), fibrosis of the trabecular network (e.g., associated with glaucoma), posterior segment fibrotic diseases of the eye, fibrovascular scarring (e.g., in retinal or choroidal vasculature of the eye), retinal fibrosis, epiretinal fibrosis, retinal gliosis, subretinal fibrosis (e.g., associated with age related macular degeneration), fibrosis associated with post-retinal and glaucoma surgery, and tractional retinal detachment in association with contraction of the tissue in diabetic retinopathy.

44. The ~~method~~ use of claim 42, wherein the disease, condition or disorder is a fibroproliferative eye disease, condition, or disorder, fibrosis of the eye, or ophthalmic fibrosis.

45. Use of an antibody of any one of claims 1-33 or a pharmaceutical composition of claim 40 for the manufacture of a medicament for ~~A method for~~ treating cancer in a subject in need thereof.~~comprising administering to a subject in need thereof a therapeutically effective amount of an antibody of any one of claims 1 to 33 or a pharmaceutical composition of claim 40.~~

46. The ~~method~~ use of claim 45, wherein the antibody or composition increases the number of natural killer (NK) cells in a tumor and/or improves NK cell cytolytic activity.

47. The ~~method~~ use of claim 45, wherein the antibody or composition decreases the number of regulatory T cells in a tumor and/or inhibits regulatory T cell function.

48. The ~~method~~use of claim 45, wherein the antibody or composition increases the number of cytotoxic T cells (CTLs) in a tumor and/or enhances CTL function.

49. The ~~method~~use of claim 45, wherein the antibody decreases the number of myeloid-derived suppressor cells (MDSC) in a tumor and/or inhibits MDSC function.

50. The ~~method~~use of claim 44, wherein the antibody decreases the number of dendritic cells (DC) in a tumor and/or inhibits the tolerogenic function of dendritic cells.

51. The ~~method~~ use of any one of claims 45 to 50, wherein the cancer is selected from the group consisting of lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma.

52. ~~A method~~Use of an antibody of any one of claims 1-33 or a pharmaceutical composition of claim 40 for the manufacture of a medicament for treating fibrosis in a subject in need thereof.~~comprising administering to a subject in need thereof a therapeutically effective amount of an antibody of any one of claims 1 to 33 or a pharmaceutical composition of claim 40.~~

53. A composition comprising an antibody of any one of claims 1 to 33 or a pharmaceutical composition of claim 40 for use in treating a condition or disorder associated with TGFβ expression.